Prognostic Factors for Survival in Melanoma Patients with Brain Metastases

Brain Metastases from Primary Tumors: Epidemiology, Biology, and Therapy of Melanoma and Other Cancers

Volumn 3, Issue , 2016, Pages 267-297

  Glitza, Isabella C ^a   Heimberger, Amy B ^a   Sulman, Erik P ^a   Davies, Michael A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Brain metastases; Central nervous system (CNS); Melanoma; Radiation; Skin cancer; Surgery; Systemic treatment

Indexed keywords

EID: 85011584031     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-803508-5.00019-6     Document Type: Chapter

References (111)

1. Agarwala S.S., Kirkwood J.M., Gore M., Dreno B., Thatcher N., Czarnetski B., et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J. Clin. Oncol. 2004, 22:2101-2107.
2. Amaravadi R.K., Schuchter L.M., McDermott D.F., Kramer A., Giles L., Gramlich K., et al. Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin. Cancer Res. 2009, 15:7711-7718.
3. Amer M.H., Al-Sarraf M., Baker L.H., Vaitkevicius V.K. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 1978, 42:660-668.
4. Anderson C.M., Buzaid A.C., Legha S.S. Systemic treatments for advanced cutaneous melanoma. Oncology 1995, 9:1149-1158.
5. Andrews D.W., Scott C.B., Sperduto P.W., Flanders A.E., Gaspar L.E., Schell M.C., et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363:1665-1672.
6. Aoyama H., Shirato H., Tago M., Nakagawa K., Toyoda T., Hatano K., et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006, 295(21):2483-2491.
7. Armstrong J.G., Wronski M., Galicich J., Arbit E., Leibel S.A., Burt M. Postoperative radiation for lung cancer metastatic to the brain. J. Clin. Oncol. 1994, 12(11):2340-2344.
8. Atkins M.B., Hsu J., Lee S., Cohen G.I., Flaherty L.E., Sosman J.A., et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. 2008, 26:5748-5754.
9. Atkins M.B., Sosman J.A., Agarwala S., Logan T., Clark J.I., Ernstoff M.S., et al. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer 2008, 113:2139-2145.
10. Ayala-Peacock D.N., Peiffer A.M., Lucas J.T., Isom S., Kuremsky J.G., Urbanic J.J., et al. A nomogram for predicting distant brain failure in patients treated with gamma knife stereotactic radiosurgery without whole brain radiotherapy. Neuro. Oncol. 2014, 16(9):1283-1288.
11. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 2009, 27(36):6199-6206.
12. Bedikian A.Y., Johnson M.M., Warneke C.L., McIntyre S., Papadopoulos N., Hwu W.J., et al. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival. J. Immunotoxicol. 2008, 5(2):201-207.
13. Bedikian A.Y., Wei C., Detry M., Kim K.B., Papadopoulos N.E., Hwu W.J., et al. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma. Am. J. Clin. Oncol. 2011, 34(6):603-610.
14. Bottoni U., Clerico R., Paolino G., Ambrifi M., Corsetti P., Calvieri S. Predictors and survival in patients with melanoma brain metastases. Med. Oncol. 2013, 30(466):1-6.
15. Bucheit A.D., Syklawer E., Jakob J.A., Bassett R.L., Curry J.L., Gershenwald J.E., et al. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer 2013, 119:3821-3829.
16. Bucheit A.D., Chen G., Siroy A., Tetzlaff M.T., Broaddus R., Milton D., et al. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin. Cancer Res. 2014, 20(21):5527-5536.
17. Buchsbaum J.C., Suh J.H., Lee S.Y., Chidel M.A., Greskovich J.F., Barnett G.H. Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer 2002, 94:2265-2272.
18. Chang E.L., Hassenbusch S.J., Shiu A.S., Lang F.F., Allen P.K., Sawaya R., et al. The role of tumor size in the radiosurgical management of patients with ambiguous brain metastases. Neurosurgery 2003, 53:272-280. Discussion 280-271.
19. Chang E.L., Wefel J.S., Hess K.R., Allen P.K., Lang F.F., Kornguth D.G., et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009, 10:1037-1044.
20. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364:2507-2516.
21. Chen G., Chakravarti N., Aardalen K., Lazar A.J., Tetzlaff M., Wubberhorst B., et al. Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin. Cancer Res. 2014, 21:5537-5546.
22. Chu M.B., Fesler M.J., Armbrecht E.S., Fosko S.W., Hsueh E., Richart J.M. High-Dose Interleukin-2 (HD IL-2) therapy should be considered for treatment of patients with melanoma brain metastases. Chemother. Res. Pract. 2013, 2013(726925):1-7.
23. Cohn-Cedermark G., Mansson-Brahme E., Rutqvist L.E., Larsson O., Johansson H., Ringborg U. Central nervous system metastases of cutaneous malignant melanoma- a population-based study. Acta Oncol. 1998, 37(5):463-470.
24. Daryanani D., Plukker J.T., de Jong M.A., Haaxma-Reiche H., Nap R., Kuiper H., et al. Increased incidence of brain metastases in cutaneous head and neck melanoma. Melanoma Res. 2005, 15:119-124.
25. Davies M.A., Liu P., McIntyre S., Kim K.B., Papadopoulos N., Hwu W.J., et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2011, 117:1687-1696.
26. Devito N., Yu M., Chen R., Pan E. Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide. Anticancer Res. 2011, 31:4537-4543.
27. Di Giacomo A.M., Ascierto P.A., Pilla L., Santinami M., Ferrucci P.F., Giannarelli D., et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 2012, 13:879-886.
28. Dzienis M.R., Atkinson V.G. Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review. Melanoma Res. 2014, 4:349-353.
29. Eigentler T.K., Figl A., Krex D., Mohr P., Mauch C., Rass K., et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 2011, 117:1697-1703.
30. Eisen T., Marais R., Affolter A., Lorigan P., Robert C., Corrie P., et al. Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. Br. J. Cancer 2011, 105:353-359.
31. Essner R. Surgical treatment of malignant melanoma. Surg. Clin. North Am. 2003, 83:109-156.
32. Falchook G.S., Long G.V., Kurzrock R., Kim K.B., Arkenau T.H., Brown M.P., et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901.
33. Farnell G.F., Buckner J.C., Cascino T.L., O'Connell M.J., Schomberg P.J., Suman V. Brain metastases from colorectal carcinoma. The long term survivors. Cancer 1996, 78:711-716.
34. Fife K.M., Colman M.H., Stevens G.N., Firth I.C., Moon D., Shannon K.F., et al. Determinants of outcome in melanoma patients with cerebral metastases. J. Clin. Oncol. 2004, 22:1293-1300.
35. Flaherty K.T., Infante J.R., Daud A., Gonzalez R., Kefford R.F., Sosman J., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 2012, 367:1694-1703.
36. Gaspar L., Scott C., Rotman M., Asbell S., Phillips T., Wasserman T., et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys. 1997, 37:745-751.
37. Golden E.B., Demaria S., Schiff P.B., Chachoua A., Formenti S.C. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol. Res. 2013, 1:365-372.
38. Grandhi R., Kondziolka D., Panczykowski D., Monaco E.A., Kano H., Niranjan A., et al. Stereotactic radiosurgery using the Leksell Gamma Knife Perfexion unit in the management of patients with 10 or more brain metastases. J. Neurosurg. 2012, 117:237-245.
39. Gumusay O., Coskun U., Akman T., Ekinci A.S., Kocar M., Erceleb O.B., et al. Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology. J. Cancer Res. Clin. Oncol. 2014, 140:151-157.
40. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 2013, 369:134-144.
41. Hamilton R., Krauze M., Romkes M., Omolo B., Konstantinopoulos P., Reinhart T., et al. Pathologic and gene expression features of metastatic melanomas to the brain. Cancer 2013, 119:2737-2746.
42. Hauschild A., Grob J.J., Demidov L.V., Jouary T., Gutzmer R., Millward M., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
43. Hofmann M.A., Coll S.H., Kuchler I., Kiecker F., Wurm R., Sterry W., et al. Prognostic factors and impact of treatment in melanoma brain metastases: better prognosis for women?. Dermatology 2007, 215:10-16.
44. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363(8):711-723.
45. Hong J.J., Rosenberg S.A., Dudley M.E., Yang J.C., White D.E., Butman J.A., et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin. Cancer Res. 2010, 16:4892-4898.
46. Hwu W.J., Lis E., Menell J.H., Panageas K.S., Lamb L.A., Merrell J., et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 2005, 103:2590-2597.
47. Jackson J.E., Burmeister B.H., Burmeister E.A., Foote M.C., Thomas J.M., Meakin J.A., et al. Melanoma brain metastases: the impact of nodal disease. Clin. Exp. Metastasis 2014, 31:81-85.
48. Jakob J.A., Bassett R.L., Ng C.S., Curry J.L., Joseph R.W., Alvarado G.C., et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012, 118:4014-4023.
49. Kim K.B., Eton O., East M.J., Hodges C., Papadopoulos N.E., Grimm E.A., et al. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Cancer 2004, 101:596-603.
50. Knisely J.P., Yu J.B., Flanigan J., Sznol M., Kluger H.M., Chiang V.L. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J. Neurosurg. 2012, 117:227-233.
51. Koay E.U., Bucheit A.D., Jakob J.A., Hyun E.D., Settle S.H., Brown P.D., et al. Correlation of BRAF and NRAS mutation status with tumor characteristics and treatment outcomes in melanoma patients with brain metastasis. J. Clin. Oncol. 2012, 30. (suppl; abstr 8584).
52. Koc M., McGregor J., Grecula J., Bauer C.J., Gupta N., Gahbauer R.A. Gamma Knife radiosurgery for intracranial metastatic melanoma: an analysis of survival and prognostic factors. J. Neurooncol. 2005, 71:307-313.
53. Kocher M., Soffietti R., Abacioglu U., Villa S., Fauchon F., Baumert B.G., et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J. Clin. Oncol. 2011, 29:134-141.
54. Konstantinou M.P., Dutriaux C., Gaudy-Marqueste C., Mortier L., Bedane C., Girard C., et al. Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients. Acta Derm. Venereol. 2014, 94:45-49.
55. Krown S.E., Niedzwiecki D., Hwu W.J., Hodgson L., Houghton A.N., Haluska F.G. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer 2006, 107:1883-1890.
56. Larkin J.M., Hughes S.A., Beirne D.A., Patel P.M., Gibbens I.M., Bate S.C., et al. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. Br. J. Cancer 2007, 96:44-48.
57. Lee I., Fox P.S., Ferguson S.D., Bassett R., Kong L.Y., Schacherer C.W., et al. The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. Oncotarget 2012, 3:336-344.
58. Lombardi G., Di Stefano A.L., Farina P., Zagonel V., Tabouret E. Systemic treatments for brain metastases from breast Cancer, non-small cell lung Cancer, melanoma and renal cell carcinoma: an overview of the literature. Cancer Treat. Rev. 2014, 8:951-959.
59. Long G.V., Trefzer U., Davies M.A., Kefford R.F., Ascierto P.A., Chapman P.B., et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012, 13:1087-1095.
60. Majer M., Jensen R.L., Shrieve D.C., Watson G.A., Wang M., Leachman S.A., et al. Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. Cancer 2007, 110:1329-1337.
61. Margolin K., Atkins B., Thompson A., Ernstoff S., Weber J., Flaherty L., et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J. Cancer Res. Clin. Oncol. 2002, 128:214-218.
62. Margolin K., Ernstoff M.S., Hamid O., Lawrence D., McDermott D., Puzanov I., et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012, 13:459-465.
63. Mathew M., Tam M., Ott P.A., Pavlick A.C., Rush S.C., Donahue B.R., et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res. 2013, 23:191-195.
64. McPherson C.M., Suki D., Feiz-Erfan I., Mahajan A., Chang E., Sawaya R., et al. Adjuvant whole-brain radiation therapy after surgical resection of single brain metastases. Neuro. Oncol. 2010, 12:711-719.
65. Meier S., Baumert B.G., Maier T., Wellis G., Burg G., Seifert B., et al. Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie 2004, 27:145-149.
66. Menzies A.M., Haydu L.E., Visintin L., Carlino M.S., Howle J.R., Thompson J.F., et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin. Cancer Res. 2012, 18:3242-3249.
67. Miller D., Zappala V., El Hindy N., Livingstone E., Schadendorf D., Sure U., et al. Intracerebral metastases of malignant melanoma and their recurrences- a clinical analysis. Clin. Neurol. Neurosurg. 2013, 115:1721-1728.
68. Mori Y., Kondziolka D., Flickinger J.C., Kirkwood J.M., Agarwala S., Lunsford L.D. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int. J. Radiat. Oncol. Biol. Phys. 1998, 42:581-589.
69. Mornex F., Thomas L., Mohr P., Hauschild A., Delaunay M.M., Lesimple T., et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res. 2003, 13:97-103.
70. Neal M.T., Chan M.D., Lucas J.T., Loganathan A., Dillingham C., Pan E., et al. Predictors of survival, neurologic death, local failure, and distant failure after gamma knife radiosurgery for melanoma brain metastases. World Neurosurg. 2013, [Epub ahead of print].
71. Nieder C., Berberich W., Schnabel K. Tumor-related prognostic factors for remission of brain metastases after radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1997, 39:25-30.
72. Niessner H., Forschner A., Klumpp B., Honegger J.B., Witte M., Bornemann A., et al. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med. 2013, 2:76-85.
73. Ojerholm E., Lee J.Y., Kolker J., Lustig R., Dorsey J.F., Alonso-Basanta M. Gamma Knife radiosurgery to four or more brain metastases in patients without prior intracranial radiation or surgery. Cancer Med. 2014, 3:565-571.
74. Osei-Boateng V.A., Dahiya S., Du L., Garje R., Elson P., Chao S.T., et al. Graded prognostic assessment index for melanoma with brain metastases (MBM). J. Clin. Oncol. 2013, 31. (suppl; abstr 9086).
75. Partl R., Richtig E., Avian A., Berghold A., Kapp K.S. Karnofsky performance status and lactate dehydrogenase predict the benefit of palliative whole-brain irradiation in patients with advanced intra- and extracranial metastases from malignant melanoma. Int. J. Radiat. Oncol. Biol. Phys. 2013, 85:662-666.
76. Patchell R.A., Tibbs P.A., Regine W.F., Dempsey R.J., Mohiuddin M., Kryscio R.J., et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998, 280:1485-1489.
77. Patchell R.A., Tibbs P.A., Walsh J.W., Dempsey R.J., Maruyama Y., Kryscio R.J., et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 1990, 322:494-500.
78. Phan G.Q., Attia P., Steinberg S.M., White D.E., Rosenberg S.A. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol. 2001, 19:3477-3482.
79. Postow M.A., Callahan M.K., Barker C.A., Yamada Y., Yuan J., Kitano S., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 2012, 366:925-931.
80. Powell S., Dudek A.Z. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases. Anticancer Res. 2009, 29:4189-4193.
81. Queirolo P., Spagnolo F., Ascierto P.A., Simeone E., Marchetti P., Scoppola A., et al. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J. Neurooncol. 2014, 118:109-116.
82. Radvanyi L.G., Bernatchez C., Zhang M., Fox P.S., Miller P., Chacon J., et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 2012, 18:6758-6770.
83. Raizer J.J., Hwu W.J., Panageas K.S., Wilton A., Baldwin D.E., Bailey E., et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro. Oncol. 2008, 10:199-207.
84. Ramakrishna N., Margolin K.A. Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases. Am. Soc. Clin. Oncol. Educ. Book 2013, 399-403.
85. Redmond A.J., Diluna M.L., Hebert R., Moliterno J.A., Desai R., Knisely J.P., et al. Gamma Knife surgery for the treatment of melanoma metastases: the effect of intratumoral hemorrhage on survival. J. Neurosurg. 2008, 109(Suppl.):99-105.
86. Rodrigues G., Warner A., Zindler J., Slotman B., Lagerwaard F. A clinical nomogram and recursive partitioning analysis to determine the risk of regional failure after radiosurgery alone for brain metastases. Radiother. Oncol. 2014, 111:52-58.
87. Rompoti N., Schilling B., Livingstone E., Griewank K., Hillen U., Sauerwein W., et al. Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicity. J. Clin. Oncol. 2013, 31:3844-3850.
88. Saha S., Meyer M., Krementz E.T., Hoda S., Carter R.D., Muchmore J., et al. Prognostic evaluation of intracranial metastasis in malignant melanoma. Ann. Surg. Oncol. 1994, 1:38-44.
89. Sampson J.H., Carter J.H., Friedman A.H., Seigler H.F. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J. Neurosurg. 1998, 88:11-20.
90. Satzger I., Degen A., Asper H., Kapp A., Hauschild A., Gutzmer R. Reply to N. Rompoti et al. J. Clin. Oncol. 2013, 31:3845-3846.
91. Sawaya R.B., Lang R., Abi-Said F.F. Metastatic brain tumors. Brain Tumors 2001, 999-1026. Churchill Livingstone, Philadelphia. second ed. A.H. Kaye, E.R. Laws (Eds.).
92. Sawrie S.M., Guthrie B.L., Spencer S.A., Nordal R.A., Meredith R.F., Markert J.M., et al. Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone. Int. J. Radiat. Oncol. Biol. Phys. 2008, 70:181-186.
93. Schoenewolf N.L., Belloni B., Simcock M., Tonolla S., Vogt P., Scherrer E., et al. Clinical implications of distinct metastasizing preferences of different melanoma subtypes. Eur. J. Dermatol. 2014, 2:236-241.
94. Schuttrumpf L.H., Niyazi M., Nachbichler S.B., Manapov F., Jansen N., Siefert A., et al. Prognostic factors for survival and radiation necrosis after stereotactic radiosurgery alone or in combination with whole brain radiation therapy for 1-3 cerebral metastases. Radiat. Oncol. 2014, 9(105):1-8.
95. Silk A.W., Bassetti M.F., West B.T., Tsien C.I., Lao C.D. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med. 2013, 2:899-906.
96. Skeie B.S., Skeie G.O., Enger P.O., Ganz J.C., Heggdal J.I., Ystevik B., et al. Gamma knife surgery in brain melanomas: absence of extracranial metastases and tumor volume strongest indicators of prolonged survival. World Neurosurg. 2011, 75:684-691.
97. Skibber J.M., Soong S.J., Austin L., Balch C.M., Sawaya R.E. Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann. Surg. Oncol. 1996, 3:118-123.
98. Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 2012, 366:707-714.
99. Sperduto P.W., Chao S.T., Sneed P.K., Luo X., Suh J., Roberge D., et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int. J. Radiat. Oncol. Biol. Phys. 2010, 77:655-661.
100. Staudt M., Lasithiotakis K., Leiter U., Meier F., Eigentler T., Bamberg M., et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br. J. Cancer 2010, 102:1213-1218.
101. Stridsklev I.C., Hagen S., Klepp O. Radiation therapy for brain metastases from malignant melanoma. Acta Radiol. Oncol. 1984, 23:231-235.
102. Topalian S.L., Sznol M., McDermott D.F., Kluger H.M., Carvajal R.D., Sharfman W.H., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 2014, 32:1020-1030.
103. Vecchio S., Spagnolo F., Merlo D.F., Signori A., Acquati M., Pronzato P., et al. The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survival. Melanoma Res. 2014, 24:61-67.
104. Vestermark L.W., Larsen S., Lindelov B., Bastholt L. A phase II study of thalidomide in patients with brain metastases from malignant melanoma. Acta Oncol. 2008, 47:1526-1530.
105. Wang J., Wei C., Noor R., Burke A., McIntyre S., Bedikian A.Y. Surveillance for brain metastases in patients receiving systemic therapy for advanced melanoma. Melanoma Res. 2014, 24:54-60.
106. Weber J.S., Amin A., Minor D., Siegel J., Berman D., O'Day S.J. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res. 2011, 21:530-534.
107. Wronski M., Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J. Neurosurg. 2000, 93:9-18.
108. Xie T.X., Wei D., Liu M., Gao A.C., Ali-Osman F., Sawaya R., et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004, 23:3550-3560.
109. Xie T.X., Huang F.J., Aldape K.D., Kang S.H., Liu M., Gershenwald J.E., et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res. 2006, 66:3188-3196.
110. Yoo H., Kim Y.Z., Nam B.H., Shin S.H., Yang H.S., Lee J.S., et al. Reduced local recurrence of a single brain metastasis through microscopic total resection. J. Neurosurg. 2009, 110:730-736.
111. Zakrzewski J., Geraghty L.N., Rose A.E., Christos P.J., Mazumdar M., Polsky D., et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer 2011, 117:1711-1720.